p62 is Negatively Implicated in the TRAF6-BECN1 Signaling Axis for Autophagy Activation and Cancer Progression by Toll-Like Receptor 4 (TLR4).


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
06 05 2020
Historique:
received: 26 03 2020
revised: 23 04 2020
accepted: 02 05 2020
entrez: 10 5 2020
pubmed: 10 5 2020
medline: 24 2 2021
Statut: epublish

Résumé

Toll-like receptors (TLRs) induce the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and autophagy through the TNF (Tumor necrosis factor) receptor-associated factor 6 (TRAF6)-evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) and TRAF6-BECN1 signaling axes, respectively. Having shown that p62 negatively regulates Toll-like receptor 4 (TLR4)-mediated signaling via TRAF6-ECSIT signaling axis, we herein investigated whether p62 is functionally implicated in the TRAF6-BECN1 signaling axis, thereby regulating cancer cell migration and invasion. p62 interacted with TRAF6 and BECN1, to interrupt the functional associations required for TRAF6-BECN1 complex formation, leading to inhibitions of BECN1 ubiquitination and autophagy activation. Importantly, p62-deficient cancer cells, such as p62-knockdown (p62

Identifiants

pubmed: 32384667
pii: cells9051142
doi: 10.3390/cells9051142
pmc: PMC7290749
pii:
doi:

Substances chimiques

Beclin-1 0
SQSTM1 protein, human 0
Sequestosome-1 Protein 0
TNF Receptor-Associated Factor 6 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Immune Netw. 2019 Jun 12;19(3):e16
pubmed: 31281713
Carcinogenesis. 2013 Jun;34(6):1343-51
pubmed: 23430956
Nat Immunol. 2001 Aug;2(8):675-80
pubmed: 11477402
Cancer Res. 2009 Dec 1;69(23):8844-52
pubmed: 19903843
EMBO J. 2000 Apr 3;19(7):1576-86
pubmed: 10747026
J Biol Chem. 2010 Nov 12;285(46):35759-69
pubmed: 20837465
Front Immunol. 2019 Sep 18;10:2203
pubmed: 31620128
Cell Death Differ. 2006 May;13(5):816-25
pubmed: 16410796
Mol Biol Cell. 2015 Jan 1;26(1):151-60
pubmed: 25355951
Genes Dev. 2003 Dec 1;17(23):2933-49
pubmed: 14633973
Autophagy. 2014 Feb;10(2):257-68
pubmed: 24321786
J Biol Chem. 2014 Dec 19;289(51):35205-14
pubmed: 25371197
Front Immunol. 2017 Dec 15;8:1827
pubmed: 29326710
Cancer Immunol Immunother. 2013 Feb;62(2):309-20
pubmed: 22923191
Mol Cell. 2013 Sep 12;51(5):618-31
pubmed: 24011591
Curr Opin Immunol. 1999 Feb;11(1):13-8
pubmed: 10047546
Methods. 2015 Mar;75:13-8
pubmed: 25484342
Cancer Cell. 2008 Apr;13(4):343-54
pubmed: 18394557
J Vis Exp. 2017 Jul 21;(125):
pubmed: 28784946
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Cancer Res. 2006 Apr 1;66(7):3859-68
pubmed: 16585214
Autophagy. 2018;14(8):1347-1358
pubmed: 29929436
PLoS One. 2013 Sep 13;8(9):e74407
pubmed: 24058558
J Immunol. 2009 Feb 15;182(4):2131-40
pubmed: 19201866
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6191-6
pubmed: 9177193
Dev Cell. 2004 Feb;6(2):303-9
pubmed: 14960283
Nature. 1999 Mar 18;398(6724):252-6
pubmed: 10094049
Oncogene. 2013 Feb 7;32(6):699-712
pubmed: 22525272
J Biol Chem. 2001 Mar 16;276(11):7709-12
pubmed: 11244088
Autophagy. 2013 Dec;9(12):2056-68
pubmed: 24157892
FEBS Lett. 2002 Feb 13;512(1-3):19-24
pubmed: 11852044
Cell Death Dis. 2016 Jul 28;7(7):e2313
pubmed: 27468689
Mol Cell Biol. 2004 Sep;24(18):8055-68
pubmed: 15340068

Auteurs

Mi-Jeong Kim (MJ)

Department of Immunology, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.

Yoon Min (Y)

Department of Immunology, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.

Ji Seon Im (JS)

Department of Immunology, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.

Juhee Son (J)

Department of Immunology, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.

Joo Sang Lee (JS)

Department of Precision Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.
Samsung Medical Center, Seoul 06351, Korea.

Ki-Young Lee (KY)

Department of Immunology, Sungkyunkwan University School of Medicine, Seobu-ro 2066, Jangan-gu, Suwon, Gyeonggi-do 16419, Korea.
Samsung Medical Center, Seoul 06351, Korea.
Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH